Efficacy and Safety of Vortioxetine and Duloxetine 60 mg Compared Placebo for the Treatment of Major Depressive Disorder: A Systematic Review and Meta-Analysis


Background: Major depressive disorder is a serious public health problem affecting the lives of millions in the worldwide and leading causes of disability and disease. This study aimed to evaluate the efficacy and safety of Vortioxetine and Duloxetine 60 mg compared to placebo for the treatment of major depressive disorder. Method: We searched the Cochrane library, Pub Med, CRD, Scopus, and Central Register of Controlled Trials to January 2015. We also searched ClinicalTrials.gov, International depressive disorder Conference and the Anxiety Disorders and Depression Conference. We identified that five randomized clinical trials were ultimately included in a Meta analysis. Data analysis was conducted by Standardized Mean Differences (SMD) for Montgomery-Åsberg Depression Rating Scale (MADRS), and Odds Ratio (OR) for adverse events. The SMD and OR reported by 95% CI. Results: Results showed statistical significance in the MADRS for Vortioxetine (SMD = ﹣3.29; 95% CI ﹣4.47 to ﹣2.10; I2 = 99.3%) and for Duloxetine 60 mg (SMD = ﹣6.35; 95% CI ﹣8.84, ﹣3.87; I2 = 99.3%). Results showed that the Vortioxetine 2.5, 5, 10, 15, 20 mg and overall compared to placebo showed a significance for Nausea and no significance for diarrhea, dry mouth, dizziness, fatigue and headache. Also results of Duloxetine 60 mg showed a significant effect for dry mouth, dizziness, fatigue and nausea. Conclusion: It is necessary to do more studies so as to better assess and much more powerful than the evidence for the use of this drug in the treatment of depression.

Share and Cite:

Behzadifar, M. , Keshavarzi, A. , Tofighian, A. , Rastian, M. , Zobidi, M. and Sari, A. (2015) Efficacy and Safety of Vortioxetine and Duloxetine 60 mg Compared Placebo for the Treatment of Major Depressive Disorder: A Systematic Review and Meta-Analysis. Journal of Behavioral and Brain Science, 5, 430-439. doi: 10.4236/jbbs.2015.510041.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Alvarez, E., Perez, V., Dragheim, M., Loft, H. and Artigas, F. (2011) A Double-Blind, Randomized, Placebo-Controlled, Active Reference Study of Vortioxetine in Patients with Major Depressive Disorder. International Journal of Neuropsychopharmacology, 15, 589-600.
[2] Bridge, J.A., Birmaher, B., Iyengar, S., Barbe, R.P. and Brent, D.A. (2009) Placebo Response in Randomized Controlled Trials of Antidepressants for Pediatric Major Depressive Disorder. American Journal of Psychiatry, 166, 42-49.
[3] Murray, C.J.L. and Lopez, A.D. (1997) Alternative Projections of Mortality and Disability by Cause 1990-2020: Global Burden of Disease Study. The Lancet, 349, 1498-1504.
[4] Liu, M.T., Maroney, M.E. and Hermes-De Santis, E.R. (2015) Levomilnacipran and Vortioxetine: Review of New Pharmacotherapies for Major Depressive Disorder. World Journal of Pharmacology, 4, 17-30.
[5] Khan, A., Bhat, A., Kolts, R., Thase, M.E. and Brown, W. (2010) Why Has the Antidepressant-Placebo Difference in Antidepressant Clinical Trials Diminished over the Past Three Decades? CNS Neuroscience and Therapeutics, 16, 217-226.
[6] Henigsberg, N., Mahableshwarkar, A., Jacobsen, P., Chen, Y.Z. and Thase, M.E. (2012) A Randomized, Double-Blind, Placebo-Controlled 8-Week Trial of the Efficacy and Tolerability of Multiple Doses of Lu AA21004 in Adults with Major Depressive Disorder. The Journal of Clinical Psychiatry, 73, 953-959.
[7] Khin, N.A., Chen, Y.-F., Yang, Y., Yang, P.L. and Laughren, T.P. (2011) Exploratory Analyses of Efficacy Data from Major Depressive Disorder Trials Submitted to the US Food and Drug Administration in Support of New Drug Applications. The Journal of Clinical Psychiatry, 72, 464-472.
[8] Pehrson, A.L., Cremers, T., Bétry, C., van der Hartb, M.G.C., Jorgensena, L., Madsen, M., et al. (2013) Lu AA21004, a Novel Multimodal Antidepressant, Produces Regionally Selective Increases of Multiple Neurotransmitters—A Rat Microdialysis and Electrophysiology Study. European Neuropsychopharmacology, 23, 133-145.
[9] Harada, E., Schacht, A., Koyama, T., Marangell, L.B., Tsuji, T. and Escobar, R. (2015) Efficacy Comparison of Duloxetine and SSRIs at Doses Approved in Japan. Neuropsychiatric Disease and Treatment, 11, 115-123.
[10] Meeker, A.S., Herink, M.C., Haxby, D.G. and Hartung, D.M. (2015) The Safety and Efficacy of Vortioxetine for Acute Treatment of Major Depressive Disorder: A Systematic Review and Meta-Analysis. Systematic Reviews, 4, 21.
[11] Liberati, A., Altman, D.G., Tetzlaff, J., Mulrow, C., Gotzsche, P.C., Ioannidis, J.P.A., et al. (2009) The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration. PLoS Medicine, 6, e1000100.
[12] Trull, T.J., Vergés, A., Wood, P.K., Jahng, S. and Sher, K.J. (2012) The Structure of Diagnostic and Statistical Manual of Mental Disorders (4th Edition, Text Revision) Personality Disorder Symptoms in a Large National Sample. Personality Disorders, 3, 355-369.
[13] Higgins, J.P., Altman, D.G., Gotzsche, P.C., Jüni, P., Moher, D., Oxman, A.D., et al. (2011) The Cochrane Collaboration’s Tool for Assessing Risk of Bias in Randomised Trials. British Medical Journal, 343, Article ID: d5928.
[14] Jadad, A.R., Moore, R.A., Carroll, D., Jenkinson, C., Reynolds, D.J., Gavaghan, D.J. and Mc Quay, H.J. (1996) Assessing the Quality of Reports of Randomized Clinical Trials: Is Blinding Necessary? Controlled Clinical Trials, 17, 1-12.
[15] Zimmerman, M., Chelminski, I. and Posternak, M. (2004) A Review of Studies of the Montgomery-Asberg Depression Rating Scale in Controls: Implications for the Definition of Remission in Treatment Studies of Depression. International Clinical Psychopharmacology, 19, 1-7.
[16] White, I.R. and Thomas, J. (2005) Standardized Mean Differences in Individually-Randomized and Cluster-Randomized Trials, with Applications to Meta-Analysis. Clinical Trials, 2, 141-151.
[17] Jose, S., George, P.S. and Mathew, A. (2008) Assessment of Confounding and Interaction Using the Mantel-Haenszel Risk Estimation Method. Asian Pacific Journal of Cancer Prevention, 9, 323-325.
[18] Huedo-Medina, T.B., Sánchez-Meca, J., Marín-Martínez, F. and Botella, J. (2006) Assessing Heterogeneity in Meta- Analysis: Q Statistic or I2 Index? Psychological Methods, 11, 193-206.
[19] Higgins, J.P.T. and Green S. (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0. The Cochrane Collaboration.
[20] Egger, M., Smith, G.D., Schneider, M. and Minder, C. (1997) Bias in Meta-Analysis Detected by a Simple, Graphical Test. British Medical Journal, 315, 629-634.
[21] Begg, C.B. and Mazumdar, M. (1994) Operating Characteristics of a Rank Correlation Test for Publication Bias. Biometrics, 50, 1088-1101.
[22] Baldwin, D.S., Loft, H. and Dragheim, M. (2012) A Randomised, Double-Blind, Placebo Controlled, Duloxetine- Referenced, Fixed-Dose Study of Three Dosages of Lu AA21004 in Acute Treatment of Major Depressive Disorder (MDD). European Neuropsychopharmacology, 22, 482-491.
[23] Katona, C., Hansen, T. and Olsen, C.K. (2012) A Randomized, Double-Blind, Placebo-Controlled, Duloxetine-Referenced, Fixed-Dose Study Comparing the Efficacy and Safety of Lu AA21004 in Elderly Patients with Major Depressive Disorder. International Clinical Psychopharmacology, 27, 215-223.
[24] Mahableshwarkar, A.R., Jacobsen, P.L. and Chen, Y. (2013) A Randomized, Double-Blind Trial of 2.5 mg and 5 mg Vortioxetine (Lu AA21004) versus Placebo for 8 Weeks in Adults with Major Depressive Disorder. Current Medical Research and Opinion, 29, 217-226.
[25] Boulenger, J.P., Loft, H. and Olsen, C.K. (2014) Efficacy and Safety of Vortioxetine (Lu AA21004), 15 and 20 mg/ Day: A Randomized, Double-Blind, Placebo-Controlled, Duloxetine-Referenced Study in the Acute Treatment of Adult Patients with Major Depressive Disorder. International Clinical Psychopharmacology, 29, 138-149.
[26] Mahableshwarkar, A.R., Jacobsen, P.L., Chen, Y., Serenko, M. and Trivedi, M.H. (2015) A Randomized, Double-Blind, Duloxetine-Referenced Study Comparing Efficacy and Tolerability of 2 Fixed Doses of Vortioxetine in the Acute Treatment of Adults with MDD. Psychopharmacology, 232, 2061-2070.
[27] Penninx, B.W., Beekman, A.T., Honig, A., Deeg, D.J., Schoevers, R.A., van Eijk, J.T. and van Tilburg, W. (2001) Depression and Cardiac Mortality: Results from a Community-Based Longitudinal Study. Archives of General Psychiatry, 58, 221-227.
[28] Schlienger, J.L. (2013) Type 2 Diabetes Complications. La Presse Médicale, 42, 839-848.
[29] Di Florio, A., Forty, L., Gordon-Smith, K., Heron, J., Jones, L., Craddock, N. and Jones, I. (2013) Perinatal Episodes across the Mood Disorder Spectrum. JAMA Psychiatry, 70, 168-175.
[30] Fu, J. and Chen, Y. (2015) The Efficacy and Safety of 5 mg/d Vortioxetine Compared to Placebo for Major Depressive Disorder: A Meta-Analysis. Psychopharmacology, 232, 7-16.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.